Evidence map›Paper›PMID 35395753›Full record

ReviewBMC public health2022

Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination - progress and challenges.

Nasir Yusuf, Robert Steinglass, Francois Gasse, Azhar Raza, Bilal Ahmed, Diana Chang Blanc, Ahmadu Yakubu, Christopher Gregory, Rania A Tohme

Open access · goldAbstract readReview
In one paragraph

Review in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Nasir YusufDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211, Geneva, Switzerland. yusufn@who.int.
Robert SteinglassIndependent Entity, Marshall, NC, USA.
Francois GasseIndependent Entity, San Antoni, Spain.
Azhar RazaProgram Division, United Nations Children Fund (UNICEF), New York, USA.
Bilal AhmedProgram Division, United Nations Children Fund (UNICEF), New York, USA.
Diana Chang BlancDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211, Geneva, Switzerland.
Ahmadu YakubuProgram Division, United Nations Children Fund (UNICEF), New York, USA.
Christopher GregoryProgram Division, United Nations Children Fund (UNICEF), New York, USA.
Rania A TohmeGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
United Nations Children's Fund · USWorld Health Organization · CHCenters for Disease Control and Prevention · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundAs of October 2021, 47 (80%) of the 59 countries, identified at highest risk for Maternal and Neonatal Tetanus (MNT), had been validated for elimination. We assessed sustainability of MNT elimination (MNTE) in 28 countries that were validated during 2011‒2020.

methodsWe assessed the attainment of the following MNTE sustainability indicators: 1) ≥ 90% coverage with three doses of Diphtheria-Tetanus-Pertussis vaccine (DTP3) among infants < 1 year, 2) ≥ 80% coverage with at least two doses of tetanus toxoid-containing vaccine (TTCV2 +) among pregnant women, 3) ≥ 80% protection at birth (PAB), 4) ≥ 70% skilled birth attendance (SBA), and 4) ≥ 80% first (ANC1) and fourth antenatal care (ANC4) visits. We assessed the introduction of TTCV booster doses. Data sources included the 2020 WHO /UNICEF Joint Reporting Forms, and the latest Demographic and Health Survey (DHS) or Multi-Indicator Cluster Surveys (MICS) for each country, if available. We reviewed literature and used DHS/MICS data to identify barriers to sustaining MNTE.

resultsOf 28 assessed countries, 7 (25%) reported ≥ 90% DTP3 coverage, 4 of 26 (16%) reported ≥ 80% TTCV2 + coverage, and 23 of 27 (85%) reported ≥ 80% PAB coverage. Based on DHS/MICS in 15 of the 28 countries, 10 (67%) achieved ≥ 70% SBA delivery, 13 (87%) achieved ≥ 80% ANC1 visit coverage, and 3 (20%) ≥ 80% ANC4 visit coverage. We observed sub-optimal coverage in many countries at the subnational level. The first, second and third booster doses of TTCV respectively have been introduced in 6 (21%), 5 (18%), and 1 (4%) of 28 countries. Only three countries conducted post-MNTE validation assessments. Barriers to MNTE sustainability included: competing program priorities, limited resources to introduce TTCV booster doses and implement corrective immunization in high-risk districts and socio-economic factors.

conclusionsDespite good performance of MNTE indicators in several countries, MNTE sustainability appears threatened in some countries. Integration and coordination of MNTE activities with other immunization activities in the context of the Immunization Agenda 2030 lifecourse vaccination strategy such as providing tetanus booster doses in school-based vaccination platforms, during measles second dose and HPV vaccination, and integrating MNTE post-validation assessments with immunization program reviews will ensure MNTE is sustained.

Indexed as

TetanusDiphtheria-Tetanus-Pertussis VaccineFemaleHumansImmunizationImmunization ProgramsInfantInfant, NewbornPregnancyVaccinationDiphtheria-Tetanus-Pertussis VaccineBooster dosesDisease eliminationSustainabilityTetanusVaccinationVaccine preventable diseases

Identifiers

PMID35395753
PMCPMC8994346
OpenAlexW4223626664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.